Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Solidago Spray (Fufang Yizhihuanghua Penwuji) is an approved traditional Chinese medicine (TCM) topical formulation developed and marketed by Guizhou Bailing Group Pharmaceutical. It is a compound herbal product featuring *Solidago decurrens* (goldenrod) as its primary active component, formulated specifically for the symptomatic relief of conditions affecting the upper respiratory tract and oral cavity. According to TCM principles, the spray functions to clear heat, detoxify, and disperse wind-heat. It is indicated for the treatment of acute and chronic pharyngitis, oral ulcers, gingival swelling and pain, halitosis, and symptoms associated with upper respiratory tract infections. The product is administered topically via the oral or nasal cavity, providing localized anti-inflammatory and analgesic effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Solidago Spray.